Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Paint The Table -- Ignore unavailable to you. Want to Upgrade?

To: Jorj X Mckie who wrote (7966)	1/2/2002 2:04:39 PM
From: AugustWest	Read Replies (1) \| Respond to of 23786

>>Charts aren't real compelling, just bouncing ideas Speaking of charts. daily comp "looks" like it is trying to come back to life. IMO, don't be fooled<GGG>

To: Jorj X Mckie who wrote (7966)	1/2/2002 3:29:32 PM
From: Libbyt	Read Replies (1) \| Respond to of 23786

does it make sense that generic pharms would be a stronger sector? That's a hard question to answer, since IMO it depends on several factors...the physician prescribing the drug, the patient's financial ability to pay for a drug that is a "name brand" and not a generic drug, and the health insurance or HMO, and what they will cover for specific drugs. Medical insurance, HMOs, PPOs all seem to have different requirements for the various treatments, and prescription coverage they will allow. What is covered by one insurance policy may not be covered by another policy. In general, IMO most insurance plans would want to save money and cover only generic drugs when possible, but they would be fighting the physicians in some cases based on the specific drug. Your question is "something to think about"...I'll ask a couple of people I know who might have better insight and better answers to your question.